It takes a VERY long time to collate and analyze the kind of complex data they got from this study, especially since there were a lot of different kinds of cancers involved in this study. We know that ovarian and pancreatic are two types that must have had good results, for them to be pursuing studies on those first.

Remember the horrible example of the company whose symbol I don't recall, which released data really quickly, thinking "everyone will see that this is really good." Well, everyone did NOT interpret it that way -- quite the opposite -- since they didn't do a good job of segregating and analyzing the data. Their stuff worked on one type of patient but not another.

So their stock took a huge dive and stayed down, because when they came out with figures that showed efficacy, people had been burned, and then the bashers accused them of "cherry-picking" which was not true. Had they waited and demonstrated that it worked on one particular subset of patients, they would be in a much better place now.

We sure don't want that for CTIX. Better to wait and get, for instance, the cover of Science or something like that.